LoginRegister
    JnJ to submit applications for at least 10 new drugs by 2023JnJ to submit applications for at least 10 new drugs by 2023
    Students appeal to PM to enforce ban on e-cigarettesStudents appeal to PM to enforce ban on e-cigarettes
    SEBI asks Fortis to recover Rs 403 crore from Singh Brothers; FHL informs HCSEBI asks Fortis to recover Rs 403 crore from Singh Brothers; FHL informs HC
    Lupin gets 4 USFDA observations after closure of pharmacovigilance inspectionLupin gets 4 USFDA observations after closure of pharmacovigilance inspection
    Mifeprex sale via mail in US; lawmakers urge USFDA to crackdown on firmsMifeprex sale via mail in US; lawmakers urge USFDA to crackdown on firms
    Improper storage kills shelf life of drugs; Health Ministry raises concernImproper storage kills shelf life of drugs; Health Ministry raises concern
    Japan: Novartis gets Government nod for cancer treatment Kymriah at cost of $305800Japan: Novartis gets Government nod for cancer treatment Kymriah at cost of $305800
    USFDA panel votes against Daiichi Sankyo blood cancer treatment QuizartinibUSFDA panel votes against Daiichi Sankyo blood cancer treatment Quizartinib
    Inflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuitInflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuit
    Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid refluxGlenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux
    Novartis recalls three lots of Promacta due to potential peanut contaminationNovartis recalls three lots of Promacta due to potential peanut contamination
    Eli Lilly gets USFDA nod for Cyramza to treat hepatocellular carcinomaEli Lilly gets USFDA nod for Cyramza to treat hepatocellular carcinoma
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X